Evonik expands API and advanced intermediates manufacturing with €36m investment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/lovelyday12)
(Image: Getty/lovelyday12)

Related tags: API, Manufacturing, Investment, Compound management, Production line

Evonik completed a €36m expansion of its contract manufacturing capabilities of API and advanced intermediates in the US and Europe.

The extension has included an addition or enhancement of a series of advanced technologies at contract manufacturing organization (CMO) Evonik’s production sites. The technologies include: high-potency active pharmaceutical ingredient (HPAPI), fermentation, methoxy polyethylene glycol (mPEGs) and continuous processing.

Jean-Luc Herbeaux, senior vice president at Evonik, told us that the number of highly-specialized chemical compounds needed for production continues to grow.

He explained that more than a dozen steps are required to manufacture these compounds and they are needed in areas including oncology; further, he told us that each complicated step can require specialized technologies like biocatalysis, continuous processes, and special containment.

“Pharma companies are often unwilling to develop or maintain such specialized capabilities. That is why market demand amongst pharmaceutical companies is growing rapidly for CMO partners that have the right mix of advanced technologies, global scale and service for the reliable industrialization and commercialization of these compounds,” ​said Herbeaux.

He said that by leveraging Evonik’s competencies as a global specialty chemical company, it can address the emerging needs of pharmaceutical customers and companies in complementary markets.

The expansion will allow customers to select a single CMO partner that has enabling technologies and manufacturing processes to scale-up. This can help reduce complexity and risk for customers, according to Herbeaux.

“In the field of enantiopure compounds, Evonik is able to apply chemocatalysis, enzymatic chemistry, fermentation and chiral pool chemistry so the customer will always get the best solution,”​ said Herbeux.

Evonik has two facilities, one in the US and one in Europe, which have both increased its assets footprint and added additional capacities to support production of HPAPI. With the expansion, Evonik will now be able to run several HPAPI projects in parallel down to an exposure level of 5ng/m3​.

Related news

Show more

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars